Himuka AM
Develops adrenomedullin-based pharmaceutical candidates HM101 and HM201 and advances them through Phase 1 clinical trials and license agreements
Sign in to see this
Social posts and the rest of this product's in-depth data are open to signed-in readers.
Sign in